Annotation Detail

Information
Associated Genes
FGFR3
Associated Variants
FGFR3 K650E
FGFR3 K650E
Associated Disease
adrenal carcinoma
Source Database
CIViC Evidence
Description
Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. Tumor shrinkage was observed in a patient with adrenal carcinoma and FGFR3-TACC3/FGFR2-CCDC6 fusions.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4861
Gene URL
https://civic.genome.wustl.edu/links/genes/23
Variant URL
https://civic.genome.wustl.edu/links/variants/1691
Rating
3
Evidence Type
Predictive
Disease
Adrenal Carcinoma
Evidence Direction
Supports
Drug
Erdafitinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
26324363
Drugs
Drug NameSensitivitySupported
ErdafitinibSensitivitytrue